Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying two different doses of quizartinib as maintenance treatment in adults with FLT3-ITD positive acute myeloid leukemia AML who are in their first complete remission and have not undergone allogeneic hematopoietic stem cell transplantation. This phase 2 trial aims to evaluate the safety and effectiveness of these doses in preventing relapse and improving survival. Participants are randomly assigned to receive either a higher or lower daily oral dose of quizartinib. The study also includes a sub-study using Holter monitoring to assess the impact of rapid heart rate changes on the drugs cardiac safety. Treatment continues for up to 87 months or until disease progression or other criteria are met. Throughout the trial, participants undergo regular assessments including monitoring for serious and general treatment-emergent adverse events, overall survival, and relapse-free survival. Heart function and safety are closely observed, particularly through Holter monitoring. The study lasts several years, with follow-up continuing up to 87 months after starting treatment to ensure comprehensive safety and efficacy data collection.